Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
30 October 2021 - 12:42AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
October 29, 2021
________________
NOVO NORDISK A/S
(Exact name
of Registrant as specified in its charter)
Novo Allé
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F
Form 20-F [X]
|
Form 40-F [ ]
|
Indicate by check mark whether the registrant by furnishing the information contained
in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange
Act of 1934.
If “Yes” is marked, indicate below the file number assigned to the registrant
in connection with Rule 12g-32(b):82-________
Novo Nordisk raises sales
and operating profit outlook for 2021
Bagsværd,
Denmark, 29 October 2021 – Novo Nordisk today announced that the full-year sales and operating profit outlook at constant
exchange rates (CER) has been raised.
In the third quarter of 2021, Novo Nordisk’s sales
increased by 15% and operating profit increased by 19%, both at CER. The operating profit increase was positively impacted by the amortisation
of the priority review voucher for Wegovy™ in the third quarter of 2020.
Profit and loss (CER)
|
First nine months 2021
|
Third quarter 2021
|
Net sales growth
|
13%
|
15%
|
Operating profit growth
|
12%
|
19%
|
Following the financial results for the first nine months of
2021, the outlook for 2021 is updated. The updated outlook is reflecting higher than expected Ozempic®
market share gains, GLP-1 market growth and obesity care sales, mainly in the US.
Outlook 2021 (CER)
|
Expectations 29 October
|
Expectations 4 August
|
Sales growth
|
12-15%
|
10-13%
|
Operating profit growth
|
12-15%
|
9-12%
|
Novo Nordisk’s full disclosure of the financial results
for the first nine months of 2021 will be published on 3 November 2021.
The above expectations are based on assumptions including
those described on pages 16 and 17 of the Financial report for the period 1 January 2021 to 30 June 2021 (Company
Announcement No 48 / 2021).
Page 2 of 2
The forward-looking statements on page 21 of the Financial
report for the period 1 January 2021 to 30 June 2021 (Company Announcement No 48 / 2021) also apply to this company announcement.
Novo Nordisk is a leading global healthcare company, founded
in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity
and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working
to prevent and ultimately cure disease. Novo Nordisk employs about 45,800 people in 80 countries and markets its products in around 170
countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO).
For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.
Further information
Media:
|
|
|
Mette Kruse Danielsen
|
+45 3079 3883
|
mkd@novonordisk.com
|
Michael Bachner (US)
|
+1 609 664 7308
|
mzyb@novonordisk.com
|
Investors:
|
|
|
Daniel Muusmann Bohsen
|
+45 3075 2175
|
dabo@novonordisk.com
|
Ann Søndermølle Rendbæk
|
+45 3075 2253
|
arnd@novonordisk.com
|
David Heiberg Landsted
|
+45 3077 6915
|
dhel@novonordisk.com
|
Mark Joseph Root
|
+1 848 213 3219
|
mjhr@novonordisk.com
|
Novo Nordisk A/S
Investor Relations
|
Novo Allé
2880 Bagsværd
Denmark
|
Telephone:
+45 4444 8888
|
Internet:
www.novonordisk.com
CVR no:
24 25 67 90
|
|
|
Company announcement No 64 / 2021
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
Date: October 29, 2021
|
NOVO NORDISK A/S
Lars Fruergaard Jørgensen
Chief Executive Officer
|
Novo Nordisk (PK) (USOTC:NONOF)
Historical Stock Chart
From Jun 2024 to Jul 2024
Novo Nordisk (PK) (USOTC:NONOF)
Historical Stock Chart
From Jul 2023 to Jul 2024